The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Parkinson Disease Drug Market Research Report 2025

Global Parkinson Disease Drug Market Research Report 2025

Publishing Date : Apr, 2025

License Type :
 

Report Code : 1705341

No of Pages : 92

Ask Your Query
Synopsis
The global market for Parkinson Disease Drug was valued at US$ 6191 million in the year 2024 and is projected to reach a revised size of US$ 9355 million by 2031, growing at a CAGR of 6.2% during the forecast period.
Most people with Parkinson"s disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.
This report aims to provide a comprehensive presentation of the global market for Parkinson Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Parkinson Disease Drug.
The Parkinson Disease Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Parkinson Disease Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Parkinson Disease Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Desitin Arzneimittel
Endo Pharmaceuticals
F.Hoffmann-La Roche
H.Lundbeck
Valeant
Apokyn
Orion
Stada Arzneimittel
US WorldMeds
Bausch Health
Segment by Type
Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Other
Segment by Application
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Parkinson Disease Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Parkinson Disease Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Sinemet-CR
1.2.3 Trastal
1.2.4 Madopar
1.2.5 COMT Inhibitor
1.2.6 Other
1.3 Market by Application
1.3.1 Global Parkinson Disease Drug Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Under 40 Years Old
1.3.3 40-65 Years Old
1.3.4 Above 65 Years Old
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Parkinson Disease Drug Market Perspective (2020-2031)
2.2 Global Parkinson Disease Drug Growth Trends by Region
2.2.1 Global Parkinson Disease Drug Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Parkinson Disease Drug Historic Market Size by Region (2020-2025)
2.2.3 Parkinson Disease Drug Forecasted Market Size by Region (2026-2031)
2.3 Parkinson Disease Drug Market Dynamics
2.3.1 Parkinson Disease Drug Industry Trends
2.3.2 Parkinson Disease Drug Market Drivers
2.3.3 Parkinson Disease Drug Market Challenges
2.3.4 Parkinson Disease Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Parkinson Disease Drug Players by Revenue
3.1.1 Global Top Parkinson Disease Drug Players by Revenue (2020-2025)
3.1.2 Global Parkinson Disease Drug Revenue Market Share by Players (2020-2025)
3.2 Global Parkinson Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Parkinson Disease Drug Revenue
3.4 Global Parkinson Disease Drug Market Concentration Ratio
3.4.1 Global Parkinson Disease Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Parkinson Disease Drug Revenue in 2024
3.5 Global Key Players of Parkinson Disease Drug Head office and Area Served
3.6 Global Key Players of Parkinson Disease Drug, Product and Application
3.7 Global Key Players of Parkinson Disease Drug, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Parkinson Disease Drug Breakdown Data by Type
4.1 Global Parkinson Disease Drug Historic Market Size by Type (2020-2025)
4.2 Global Parkinson Disease Drug Forecasted Market Size by Type (2026-2031)
5 Parkinson Disease Drug Breakdown Data by Application
5.1 Global Parkinson Disease Drug Historic Market Size by Application (2020-2025)
5.2 Global Parkinson Disease Drug Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Parkinson Disease Drug Market Size (2020-2031)
6.2 North America Parkinson Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Parkinson Disease Drug Market Size by Country (2020-2025)
6.4 North America Parkinson Disease Drug Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Parkinson Disease Drug Market Size (2020-2031)
7.2 Europe Parkinson Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Parkinson Disease Drug Market Size by Country (2020-2025)
7.4 Europe Parkinson Disease Drug Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Parkinson Disease Drug Market Size (2020-2031)
8.2 Asia-Pacific Parkinson Disease Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Parkinson Disease Drug Market Size by Region (2020-2025)
8.4 Asia-Pacific Parkinson Disease Drug Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Parkinson Disease Drug Market Size (2020-2031)
9.2 Latin America Parkinson Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Parkinson Disease Drug Market Size by Country (2020-2025)
9.4 Latin America Parkinson Disease Drug Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Parkinson Disease Drug Market Size (2020-2031)
10.2 Middle East & Africa Parkinson Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Parkinson Disease Drug Market Size by Country (2020-2025)
10.4 Middle East & Africa Parkinson Disease Drug Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Parkinson Disease Drug Introduction
11.1.4 Merck Revenue in Parkinson Disease Drug Business (2020-2025)
11.1.5 Merck Recent Development
11.2 Akorn
11.2.1 Akorn Company Details
11.2.2 Akorn Business Overview
11.2.3 Akorn Parkinson Disease Drug Introduction
11.2.4 Akorn Revenue in Parkinson Disease Drug Business (2020-2025)
11.2.5 Akorn Recent Development
11.3 GSK
11.3.1 GSK Company Details
11.3.2 GSK Business Overview
11.3.3 GSK Parkinson Disease Drug Introduction
11.3.4 GSK Revenue in Parkinson Disease Drug Business (2020-2025)
11.3.5 GSK Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Parkinson Disease Drug Introduction
11.4.4 Novartis Revenue in Parkinson Disease Drug Business (2020-2025)
11.4.5 Novartis Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Details
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Parkinson Disease Drug Introduction
11.5.4 Boehringer Ingelheim Revenue in Parkinson Disease Drug Business (2020-2025)
11.5.5 Boehringer Ingelheim Recent Development
11.6 Teva Pharmaceutical
11.6.1 Teva Pharmaceutical Company Details
11.6.2 Teva Pharmaceutical Business Overview
11.6.3 Teva Pharmaceutical Parkinson Disease Drug Introduction
11.6.4 Teva Pharmaceutical Revenue in Parkinson Disease Drug Business (2020-2025)
11.6.5 Teva Pharmaceutical Recent Development
11.7 Abbvie
11.7.1 Abbvie Company Details
11.7.2 Abbvie Business Overview
11.7.3 Abbvie Parkinson Disease Drug Introduction
11.7.4 Abbvie Revenue in Parkinson Disease Drug Business (2020-2025)
11.7.5 Abbvie Recent Development
11.8 Kyowa Hakko Kirin Pharma
11.8.1 Kyowa Hakko Kirin Pharma Company Details
11.8.2 Kyowa Hakko Kirin Pharma Business Overview
11.8.3 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Introduction
11.8.4 Kyowa Hakko Kirin Pharma Revenue in Parkinson Disease Drug Business (2020-2025)
11.8.5 Kyowa Hakko Kirin Pharma Recent Development
11.9 Astellas Pharma
11.9.1 Astellas Pharma Company Details
11.9.2 Astellas Pharma Business Overview
11.9.3 Astellas Pharma Parkinson Disease Drug Introduction
11.9.4 Astellas Pharma Revenue in Parkinson Disease Drug Business (2020-2025)
11.9.5 Astellas Pharma Recent Development
11.10 Desitin Arzneimittel
11.10.1 Desitin Arzneimittel Company Details
11.10.2 Desitin Arzneimittel Business Overview
11.10.3 Desitin Arzneimittel Parkinson Disease Drug Introduction
11.10.4 Desitin Arzneimittel Revenue in Parkinson Disease Drug Business (2020-2025)
11.10.5 Desitin Arzneimittel Recent Development
11.11 Endo Pharmaceuticals
11.11.1 Endo Pharmaceuticals Company Details
11.11.2 Endo Pharmaceuticals Business Overview
11.11.3 Endo Pharmaceuticals Parkinson Disease Drug Introduction
11.11.4 Endo Pharmaceuticals Revenue in Parkinson Disease Drug Business (2020-2025)
11.11.5 Endo Pharmaceuticals Recent Development
11.12 F.Hoffmann-La Roche
11.12.1 F.Hoffmann-La Roche Company Details
11.12.2 F.Hoffmann-La Roche Business Overview
11.12.3 F.Hoffmann-La Roche Parkinson Disease Drug Introduction
11.12.4 F.Hoffmann-La Roche Revenue in Parkinson Disease Drug Business (2020-2025)
11.12.5 F.Hoffmann-La Roche Recent Development
11.13 H.Lundbeck
11.13.1 H.Lundbeck Company Details
11.13.2 H.Lundbeck Business Overview
11.13.3 H.Lundbeck Parkinson Disease Drug Introduction
11.13.4 H.Lundbeck Revenue in Parkinson Disease Drug Business (2020-2025)
11.13.5 H.Lundbeck Recent Development
11.14 Valeant
11.14.1 Valeant Company Details
11.14.2 Valeant Business Overview
11.14.3 Valeant Parkinson Disease Drug Introduction
11.14.4 Valeant Revenue in Parkinson Disease Drug Business (2020-2025)
11.14.5 Valeant Recent Development
11.15 Apokyn
11.15.1 Apokyn Company Details
11.15.2 Apokyn Business Overview
11.15.3 Apokyn Parkinson Disease Drug Introduction
11.15.4 Apokyn Revenue in Parkinson Disease Drug Business (2020-2025)
11.15.5 Apokyn Recent Development
11.16 Orion
11.16.1 Orion Company Details
11.16.2 Orion Business Overview
11.16.3 Orion Parkinson Disease Drug Introduction
11.16.4 Orion Revenue in Parkinson Disease Drug Business (2020-2025)
11.16.5 Orion Recent Development
11.17 Stada Arzneimittel
11.17.1 Stada Arzneimittel Company Details
11.17.2 Stada Arzneimittel Business Overview
11.17.3 Stada Arzneimittel Parkinson Disease Drug Introduction
11.17.4 Stada Arzneimittel Revenue in Parkinson Disease Drug Business (2020-2025)
11.17.5 Stada Arzneimittel Recent Development
11.18 US WorldMeds
11.18.1 US WorldMeds Company Details
11.18.2 US WorldMeds Business Overview
11.18.3 US WorldMeds Parkinson Disease Drug Introduction
11.18.4 US WorldMeds Revenue in Parkinson Disease Drug Business (2020-2025)
11.18.5 US WorldMeds Recent Development
11.19 Bausch Health
11.19.1 Bausch Health Company Details
11.19.2 Bausch Health Business Overview
11.19.3 Bausch Health Parkinson Disease Drug Introduction
11.19.4 Bausch Health Revenue in Parkinson Disease Drug Business (2020-2025)
11.19.5 Bausch Health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
List of Tables
Table 1. Global Parkinson Disease Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Sinemet-CR
Table 3. Key Players of Trastal
Table 4. Key Players of Madopar
Table 5. Key Players of COMT Inhibitor
Table 6. Key Players of Other
Table 7. Global Parkinson Disease Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Parkinson Disease Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Parkinson Disease Drug Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Parkinson Disease Drug Market Share by Region (2020-2025)
Table 11. Global Parkinson Disease Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Parkinson Disease Drug Market Share by Region (2026-2031)
Table 13. Parkinson Disease Drug Market Trends
Table 14. Parkinson Disease Drug Market Drivers
Table 15. Parkinson Disease Drug Market Challenges
Table 16. Parkinson Disease Drug Market Restraints
Table 17. Global Parkinson Disease Drug Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Parkinson Disease Drug Market Share by Players (2020-2025)
Table 19. Global Top Parkinson Disease Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Parkinson Disease Drug as of 2024)
Table 20. Ranking of Global Top Parkinson Disease Drug Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Parkinson Disease Drug Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Parkinson Disease Drug, Headquarters and Area Served
Table 23. Global Key Players of Parkinson Disease Drug, Product and Application
Table 24. Global Key Players of Parkinson Disease Drug, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Parkinson Disease Drug Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Parkinson Disease Drug Revenue Market Share by Type (2020-2025)
Table 28. Global Parkinson Disease Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Parkinson Disease Drug Revenue Market Share by Type (2026-2031)
Table 30. Global Parkinson Disease Drug Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Parkinson Disease Drug Revenue Market Share by Application (2020-2025)
Table 32. Global Parkinson Disease Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Parkinson Disease Drug Revenue Market Share by Application (2026-2031)
Table 34. North America Parkinson Disease Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Parkinson Disease Drug Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Parkinson Disease Drug Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Parkinson Disease Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Parkinson Disease Drug Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Parkinson Disease Drug Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Parkinson Disease Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Parkinson Disease Drug Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Parkinson Disease Drug Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Parkinson Disease Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Parkinson Disease Drug Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Parkinson Disease Drug Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Parkinson Disease Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Parkinson Disease Drug Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Parkinson Disease Drug Market Size by Country (2026-2031) & (US$ Million)
Table 49. Merck Company Details
Table 50. Merck Business Overview
Table 51. Merck Parkinson Disease Drug Product
Table 52. Merck Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 53. Merck Recent Development
Table 54. Akorn Company Details
Table 55. Akorn Business Overview
Table 56. Akorn Parkinson Disease Drug Product
Table 57. Akorn Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 58. Akorn Recent Development
Table 59. GSK Company Details
Table 60. GSK Business Overview
Table 61. GSK Parkinson Disease Drug Product
Table 62. GSK Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 63. GSK Recent Development
Table 64. Novartis Company Details
Table 65. Novartis Business Overview
Table 66. Novartis Parkinson Disease Drug Product
Table 67. Novartis Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 68. Novartis Recent Development
Table 69. Boehringer Ingelheim Company Details
Table 70. Boehringer Ingelheim Business Overview
Table 71. Boehringer Ingelheim Parkinson Disease Drug Product
Table 72. Boehringer Ingelheim Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 73. Boehringer Ingelheim Recent Development
Table 74. Teva Pharmaceutical Company Details
Table 75. Teva Pharmaceutical Business Overview
Table 76. Teva Pharmaceutical Parkinson Disease Drug Product
Table 77. Teva Pharmaceutical Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 78. Teva Pharmaceutical Recent Development
Table 79. Abbvie Company Details
Table 80. Abbvie Business Overview
Table 81. Abbvie Parkinson Disease Drug Product
Table 82. Abbvie Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 83. Abbvie Recent Development
Table 84. Kyowa Hakko Kirin Pharma Company Details
Table 85. Kyowa Hakko Kirin Pharma Business Overview
Table 86. Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product
Table 87. Kyowa Hakko Kirin Pharma Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 88. Kyowa Hakko Kirin Pharma Recent Development
Table 89. Astellas Pharma Company Details
Table 90. Astellas Pharma Business Overview
Table 91. Astellas Pharma Parkinson Disease Drug Product
Table 92. Astellas Pharma Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 93. Astellas Pharma Recent Development
Table 94. Desitin Arzneimittel Company Details
Table 95. Desitin Arzneimittel Business Overview
Table 96. Desitin Arzneimittel Parkinson Disease Drug Product
Table 97. Desitin Arzneimittel Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 98. Desitin Arzneimittel Recent Development
Table 99. Endo Pharmaceuticals Company Details
Table 100. Endo Pharmaceuticals Business Overview
Table 101. Endo Pharmaceuticals Parkinson Disease Drug Product
Table 102. Endo Pharmaceuticals Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 103. Endo Pharmaceuticals Recent Development
Table 104. F.Hoffmann-La Roche Company Details
Table 105. F.Hoffmann-La Roche Business Overview
Table 106. F.Hoffmann-La Roche Parkinson Disease Drug Product
Table 107. F.Hoffmann-La Roche Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 108. F.Hoffmann-La Roche Recent Development
Table 109. H.Lundbeck Company Details
Table 110. H.Lundbeck Business Overview
Table 111. H.Lundbeck Parkinson Disease Drug Product
Table 112. H.Lundbeck Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 113. H.Lundbeck Recent Development
Table 114. Valeant Company Details
Table 115. Valeant Business Overview
Table 116. Valeant Parkinson Disease Drug Product
Table 117. Valeant Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 118. Valeant Recent Development
Table 119. Apokyn Company Details
Table 120. Apokyn Business Overview
Table 121. Apokyn Parkinson Disease Drug Product
Table 122. Apokyn Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 123. Apokyn Recent Development
Table 124. Orion Company Details
Table 125. Orion Business Overview
Table 126. Orion Parkinson Disease Drug Product
Table 127. Orion Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 128. Orion Recent Development
Table 129. Stada Arzneimittel Company Details
Table 130. Stada Arzneimittel Business Overview
Table 131. Stada Arzneimittel Parkinson Disease Drug Product
Table 132. Stada Arzneimittel Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 133. Stada Arzneimittel Recent Development
Table 134. US WorldMeds Company Details
Table 135. US WorldMeds Business Overview
Table 136. US WorldMeds Parkinson Disease Drug Product
Table 137. US WorldMeds Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 138. US WorldMeds Recent Development
Table 139. Bausch Health Company Details
Table 140. Bausch Health Business Overview
Table 141. Bausch Health Parkinson Disease Drug Product
Table 142. Bausch Health Revenue in Parkinson Disease Drug Business (2020-2025) & (US$ Million)
Table 143. Bausch Health Recent Development
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
Table 147. Authors List of This Report


List of Figures
Figure 1. Parkinson Disease Drug Picture
Figure 2. Global Parkinson Disease Drug Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Parkinson Disease Drug Market Share by Type: 2024 VS 2031
Figure 4. Sinemet-CR Features
Figure 5. Trastal Features
Figure 6. Madopar Features
Figure 7. COMT Inhibitor Features
Figure 8. Other Features
Figure 9. Global Parkinson Disease Drug Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Parkinson Disease Drug Market Share by Application: 2024 VS 2031
Figure 11. Under 40 Years Old Case Studies
Figure 12. 40-65 Years Old Case Studies
Figure 13. Above 65 Years Old Case Studies
Figure 14. Parkinson Disease Drug Report Years Considered
Figure 15. Global Parkinson Disease Drug Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Parkinson Disease Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Parkinson Disease Drug Market Share by Region: 2024 VS 2031
Figure 18. Global Parkinson Disease Drug Market Share by Players in 2024
Figure 19. Global Top Parkinson Disease Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Parkinson Disease Drug as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Parkinson Disease Drug Revenue in 2024
Figure 21. North America Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Parkinson Disease Drug Market Share by Country (2020-2031)
Figure 23. United States Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Parkinson Disease Drug Market Share by Country (2020-2031)
Figure 27. Germany Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Parkinson Disease Drug Market Share by Region (2020-2031)
Figure 35. China Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Parkinson Disease Drug Market Share by Country (2020-2031)
Figure 43. Mexico Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Parkinson Disease Drug Market Share by Country (2020-2031)
Figure 47. Turkey Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Parkinson Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Merck Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 51. Akorn Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 52. GSK Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 53. Novartis Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 54. Boehringer Ingelheim Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 55. Teva Pharmaceutical Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 56. Abbvie Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 57. Kyowa Hakko Kirin Pharma Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 58. Astellas Pharma Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 59. Desitin Arzneimittel Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 60. Endo Pharmaceuticals Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 61. F.Hoffmann-La Roche Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 62. H.Lundbeck Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 63. Valeant Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 64. Apokyn Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 65. Orion Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 66. Stada Arzneimittel Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 67. US WorldMeds Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 68. Bausch Health Revenue Growth Rate in Parkinson Disease Drug Business (2020-2025)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock